Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
HomeLetteratura (Page 3)

Though recent reports link SARS-CoV-2 infections with hyper-inflammatory states in children, most children experience no/mild symptoms, and hospitalization and mortality rates are low in the age group. As symptoms are usually mild and seroconversion occurs at low frequencies, it remains unclear whether children significantly contribute to community transmission. Several hypotheses try to

Clinical Immunology 2020:108588. /  Felsenstein S, Hedrich CM.

Objective: The development of oncology day-hospital activities contributes to increase quality of life of patients and consequently have changed their perception about waiting. The extemporaneous preparation of antineoplastic has become difficult to achieve given the increasing activity, and hospital pharmacists have taken up the challenge by the implementation of the antineoplastic

J Oncol Pharm Pract 2020 Oct 27 [Online ahead of print] /  Desmaris RP, Elisabeth Bermudez E, Annereau M, et al.

Introduction: Although consistent use of tyrosine kinase inhibitors (TKIs) confers significant improvements in long-term survival for individuals with chronic myeloid leukemia (CML), only 70% of CML patients are adherent to TKIs. Understanding the factors that contribute to non-adherence and establishing dynamic adherence patterns in this population are essential aspects of targeted

Pharm Pract 2020 Nov 11 [Online ahead of print] /  Clark SE, Marcum ZA, Radich JP, Bansal A.

Background: The list of oral and expensive chemotherapy agents has lengthened over the last few years and has created unique medication adherence concerns. In a real-life setting, patients often do not take their medications as prescribed. This pattern is associated with poor outcomes and increased health care costs. Objectives: To estimate

Int J Clin Pharm 2020;42:1311–1318. /  Matti N, Delon C, Rybarczyk-Vigouret MC, et al.

Background: Patients with haematological malignancies are at high risk of invasive fungal infections. However, there is a lack of information about the utilisation of the recommended Australian antifungal prophylaxis guidelines in haematology outpatients. Objective: To assess the impact of a weekly pharmacist review of high-risk adult haematology outpatients on the utilisation

International Journal of Clinical Pharmacy 2020; 42:1412–1418. /  Reslan Z, Lindsay J, Kerridge I, et al.

Purpose of review: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a valuable new treatment option for patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. The aim of this review is to give an overview of the pivotal phase I/II trials, emerging real-world evidence and ongoing trials. Recent findings: For decades, attempts at

Curr Opin Oncol 2020; 32(5):408-417. /  Kersten MJ, Spanjaart AM, Thieblemont C.

The COVID-19 pandemic has rapidly changed delivery of cancer care. Many nonurgent surgeries are delayed to preserve hospital resources, and patient visits to health care settings are limited to reduce exposure to SARS-CoV-2. Providers must carefully weigh risks and benefits of delivering immunosuppressive therapy during the pandemic. For breast cancer, a

JCO Oncol Pract 2020;16(10):665-674. /  Sheng JY, Santa-Maria CA, Mangini N, et al.

Background: Since the outbreak of novel coronavirus disease (COVID-19) in Wuhan, China at the beginning of December 2019, there have been over 11,200,000 confirmed cases in the world as of the 3rd July 2020, affecting over 213 countries and regions with nearly 530,000 deaths. The pandemic has been sweeping all

J Thorac Dis 2020;12(10):5739-5755. /  Zhou Y, Li J,  Chen Z, et al.

The lockdown measures of the ongoing COVID-19 pandemic have disengaged patients with cancer from formal health care settings, leading to an increased use of social media platforms to address unmet needs and expectations. Although remote health technologies have addressed some of the medical needs, the emotional and mental well-being of these

Oncologist 2020 Nov 18. Online ahead of print. /  Moraliyage H, De Silva D, Ranasinghe W, et al.

Introduction: In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method: The data of 16 laboratory-confirmed COVID-19 patients with CML receiving TKI and age, gender, and comorbid disease matched COVID-19 patients without cancer at a 3/1 ratio (n = 48), diagnosed between

J Oncol Pharm Pract 2020;26(7):1676-1682. /  Başcı S, Ata N, Altuntaş F, et al.